Nair JJ, Singh TP. Sjogren’s syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions. J Clin Exp Dent. 2017;9(4):e584-9.

 

doi:10.4317/jced.53605

http://dx.doi.org/doi:10.4317/jced.53605

 

References

1. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. Immunopathogenesis of Sjogren's syndrome. Clin Rev Allergy Immunol. 2003;25:89-104.
https://doi.org/10.1385/CRIAI:25:1:89

PMid:12794264

 

2. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum. 2000;43:1647-54.
https://doi.org/10.1002/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P

PMid:10902771

 

3. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford). 2006;45:iii3-4.
https://doi.org/10.1093/rheumatology/kel282
PMid:16987829

 

4. Harley J, Scofield R, Reichlin M. Anti-Ro in Sjogren's syndrome and systemic lupus erythematosus. Rheumatic diseases clinics of North America. 1992;18:337-58.
PMid:1626073

 

5. Shearn MA. Sjögren's syndrome in association with scleroderma. Annals of internal medicine. 1960;52:1352-62.
https://doi.org/10.7326/0003-4819-52-6-1352
PMid:14445694

 

6. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Archives of internal medicine. 2004;164:1275-84.
https://doi.org/10.1001/archinte.164.12.1275
PMid:15226160

 

7. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

PMid:19622551 PMCid:PMC2714657

 

8. Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch J-A, Toussirot E, et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine. 2005;84:81-9.
https://doi.org/10.1097/01.md.0000157397.30055.c9
PMid:15758837

 

9. Bell M, Askari A, Bookman A, Frydrych S, Lamont J, McComb J, et al. Sjogren's syndrome: a critical review of clinical management. The Journal of rheumatology. 1999;26:2051-61.
PMid:10493692

 

10. Carsons S. A review and update of Sjogren's syndrome: manifestations, diagnosis, and treatment. The American journal of managed care. 2001;7:S433-43.
PMid:11605978

 

11. Tishler M, Barak Y, Paran D, Yaron M. Sleep disturbances, fibromyalgia and primary Sjogren's syndrome. Clin Exp Rheumatol. 1997;15:71-4.
PMid:9093776

 

12. Kang HI, Fei HM, Saito I, Sawada S, Chen SL, Yi D, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren's syndrome. J Immunol. 1993;150:3615-23.
PMid:8468491

 

13. Miyagawa S, Shinohara K, Nakajima M, Kidoguchi K, Fujita T, Fukumoto T, et al. Polymorphisms of HLA class II genes and autoimmune responses to Ro/SS-A-La/SS-B among Japanese subjects. Arthritis Rheum. 1998;41:927-34.
https://doi.org/10.1002/1529-0131(199805)41:5<927::AID-ART21>3.0.CO;2-R

PMid:9588746

 

14. Jonsson R, Moen K, Vestrheim D, Szodoray P. Current issues in Sjogren's syndrome. Oral diseases. 2002;8:130-40.
https://doi.org/10.1034/j.1601-0825.2002.02846.x
PMid:12108757

 

15. Pflugfelder SC, Crouse CA, Monroy D, Yen M, Rowe M, Atherton SS. Epstein-Barr virus and the lacrimal gland pathology of Sjogren's syndrome. Am J Pathol. 1993;143:49-64.
PMid:8391219 PMCid:PMC1886957

 

16. Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice. Nature. 1989;341:72-4.
https://doi.org/10.1038/341072a0
PMid:2788824

 

17. Shim GJ, Warner M, Kim HJ, Andersson S, Liu L, Ekman J, et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A. 2004;101:12628-33.
https://doi.org/10.1073/pnas.0405099101
PMid:15314222 PMCid:PMC515108

 

18. Ishimaru N, Arakaki R, Yoshida S, Yamada A, Noji S, Hayashi Y. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjogren's syndrome-like autoimmune exocrinopathy. J Exp Med. 2008;205:2915-27.
https://doi.org/10.1084/jem.20080174
PMid:19015307 PMCid:PMC2585852

 

19. Valtysdottir ST, Wide L, Hallgren R. Mental wellbeing and quality of sexual life in women with primary Sjogren's syndrome are related to circulating dehydroepiandrosterone sulphate. Ann Rheum Dis. 2003;62:875-9.
https://doi.org/10.1136/ard.62.9.875
PMid:12922962 PMCid:PMC1754646

 

20. Brennan MT, Sankar V, Leakan RA, Grisius MM, Collins MT, Fox PC, et al. Sex steroid hormones in primary Sjogren's syndrome. J Rheumatol. 2003;30:1267-71.
PMid:12784401

 

21. Sullivan DA, Belanger A, Cermak JM, Berube R, Papas AS, Sullivan RM, et al. Are women with Sjogren's syndrome androgen-deficient? J Rheumatol. 2003;30:2413-9.
PMid:14677186

 

22. Taiym S, Haghighat N, Al-Hashimi I. A comparison of the hormone levels in patients with Sjogren's syndrome and healthy controls. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2004;97:579-83.
https://doi.org/10.1016/j.tripleo.2003.10.033

PMid:15153869

 

23. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol. 2010;6:529-37.
https://doi.org/10.1038/nrrheum.2010.118
PMid:20683439

 

24. Spachidou MP, Bourazopoulou E, Maratheftis CI, Kapsogeorgou EK, Moutsopoulos HM, Tzioufas AG, et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol. 2007;147:497-503.
https://doi.org/10.1111/j.1365-2249.2006.03311.x
PMid:17302899 PMCid:PMC1810489

 

25. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534-44.
https://doi.org/10.1002/art.21006
PMid:15880807

 

26. Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med. 2009;38:42-7.
https://doi.org/10.1111/j.1600-0714.2008.00700.x
PMid:19192049 PMCid:PMC2763314

 

27. Li R, Xie J, Kantor C, Koistinen V, Altieri DC, Nortamo P, et al. A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18. J Cell Biol. 1995;129:1143-53.
https://doi.org/10.1083/jcb.129.4.1143
PMid:7744962

 

28. Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjogren's syndrome. Arch Med Res. 2006;37:921-32.
https://doi.org/10.1016/j.arcmed.2006.08.002
PMid:17045106

 

29. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol. 2002;128:562-8.
https://doi.org/10.1046/j.1365-2249.2002.01869.x
PMid:12067313 PMCid:PMC1906267

 

30. Daridon C, Devauchelle V, Hutin P, Berre RL, Martins-Carvalho C, Bendaoud B, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis & Rheumatism. 2007;56:1134-44.
https://doi.org/10.1002/art.22458
PMid:17393395

 

31. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest. 2002;109:59-68.
https://doi.org/10.1172/JCI0214121
PMid:11781351 PMCid:PMC150825

 

32. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453-66.
https://doi.org/10.1084/jem.192.10.1453
PMid:11085747 PMCid:PMC2193190

 

33. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-710.
https://doi.org/10.1084/jem.190.11.1697
PMid:10587360 PMCid:PMC2195729

 

34. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol. 2005;25:189-201.
https://doi.org/10.1007/s10875-005-4091-5
PMid:15981083

 

35. Thorn M, Lewis RH, Mumbey-Wafula A, Kantrowitz S, Spatz LA. BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion. Cell Immunol. 2010;261:9-22.
https://doi.org/10.1016/j.cellimm.2009.10.004
PMid:19914608 PMCid:PMC2812582

 

36. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62:168-71.
https://doi.org/10.1136/ard.62.2.168
PMid:12525388 PMCid:PMC1754442

 

37. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nature immunology. 2001;2:764-6.
https://doi.org/10.1038/ni0901-764
PMid:11526379

 

38. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.
https://doi.org/10.1186/ar2506
PMid:18786258 PMCid:PMC2592791

 

39. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142-50.
https://doi.org/10.1002/art.23047
PMid:18050206

 

40. Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol. 2006;168:476-89.
https://doi.org/10.2353/ajpath.2006.050600
PMid:16436662 PMCid:PMC1606502

 

41. Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2346-54.
https://doi.org/10.3899/jrheum.101295
PMid:21965648

 

42. Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem. 2011;286:36478-91.
https://doi.org/10.1074/jbc.M111.241786
PMid:21862588 PMCid:PMC3196112

 

43. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
PMid:7506951

 

44. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-50.
https://doi.org/10.1002/art.21260
PMid:16142737

 

45. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996;14:555-8.
PMid:8913659